jak2-v617f mutation combined with philadelphia chromosome-positive chronic myeloid leukaemia: a case report
نویسندگان
چکیده
myeloproliferative neoplasms (mpns) such as polycythemia vera, essential thrombocythemia, primary myelofibrosis and chronic myeloid leukemia have too similar and accurate way to differentiate their is study of genetic disorders in these patients. philadelphia chromosome is a sure way to definitively diagnose cml. recently, jak2v617f mutation introduced as a diagnostic marker for other myeloproliferative neoplasms. many studies show that the absence of the jak2 mutation in chronic phase philadelphia positive cml. in contrast with these reports, more recently, several cases with the coexistence of philadelphia positive chromosome and jak2v617f mutation in blood and bone marrow samples were reported. here, we report a patient that have the philadelphia chromosome disorder and jak2v617f mutation in same time.
منابع مشابه
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.
In July, 2000, a 50-year-old man presented with leukocytosis and splenomegaly (21 cm). Leucocyte concentration was 93×10/L, haemoglobin 150 g/L, and platelets 345×10/L (fi gure 1). A diff erential blood count showed 54% neutrophils, 2% lymphocytes, 13% myelocytes, 7% metamyelocytes, 2% promyelocytes, 1% blasts, and 7% basophils. Lactate dehydrogenase (LDH) concentration was increased at 484 U/L...
متن کاملjak2-v617f mutation and philadelphia positive chronic myeloid leukemia
jak2 is a tyrosine kinase that plays an important role in the signaling pathways of many hematopoietic growth factor receptors. a single acquired point mutation – v617f – in jak2 occurs in the great majority of patients with polycythemia vera (pv) and approximately half of the patients with idiopathic myelofibrosis (imf) or essential thrombocythemia (et). in contrast, the jak2-v617f mutation is...
متن کاملJAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.
JAK2 is a tyrosine kinase that plays an important role in the signaling pathways of many hematopoietic growth factor receptors. A single acquired point mutation – V617F – in JAK2 occurs in the great majority of patients with polycythemia vera (PV) and approximately half of the patients with idiopathic myelofibrosis (IMF) or essential thrombocythemia (ET). In contrast, the JAK2-V617F mutation is...
متن کاملFrequency of JAK2 V617F mutation in patients with Philadelphia positive Chronic Myeloid Leukemia in Pakistan
BACKGROUND AND OBJECTIVE Co-existence of myeloproliferative disorders (MPD) and Janus associated kinase 2 mutation (JAK2 V617F) is a well-established fact. Only few case reports are available showing presence of JAK2 V617F mutation in chronic myeloid leukemia (CML). Purpose of this study was to determine the frequency of JAK2 V617F mutation in Philadelphia Chromosome positive (Ph (+)) CML patie...
متن کاملChronic neutrophilic leukemia with JAK2 V617F mutation: a case report
Chronic neutrophilic leukemia (CNL) is a rare disease grouped by World Health Organization under the broader category of chronic myeloproliferative diseases. It is a diagnosis of exclusion in patients with sustained mature neutrophilia and splenomegaly with no evidence of other myeloproliferative diseases or reactive neutrophilia. JAK2V617F mutation has been described in classical myeloprolifer...
متن کاملCoexistence of BCR-ABL1 Translocation and JAK2 V617F Mutation in a Patient with Chronic Myeloid Leukemia Under Long-term Treatment with Imatinib and Nilotinib: A Case Report
This report describes an 89-year-old woman diagnosed with Philadelphia positive Chronic Myeloid Leukemia in 2007 who was initially treated with 200 mg/day imatinib. The patient demonstrated complete molecular response (CMR) in two tests in 2015 and 2018. During treatment between 2007 and 2019, despite increased dosage of imatinib and switching her therapy to nilotinib, complete hematological r...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
international journal of hematology-oncology and stem cell researchجلد ۵، شماره ۲، صفحات ۳۴-۳۷
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023